Login / Signup

A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.

Kartik SehgalAnthony SerritellaMofei LiuAnne ONeillChaitali NangiaTheodora PappaMichael J DemeureFrancis P WordenRobert HaddadJochen Lorch
Published in: The Journal of clinical endocrinology and metabolism (2024)
NCT02244463.
Keyphrases
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • open label
  • placebo controlled